The global demand for Pulmonary Drug Delivery Devices Market is presumed to reach the valuation of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period of 2022-2028.
Pulmonary drug delivery devices are devices used for delivering drug formulation through the mouth by inhalation. The inhaled drug deposits in the lower airways treat pulmonary diseases like bronchial asthma and cystic fibrosis. These devices fall under three different classes, like metered-dose inhalers, nebulizers, and dry powder inhalers. The delivery mechanism chosen depends on the type of drug formulation, the site of action, and the lungs' pathophysiology. Relatively small amounts of molecules are used to deliver substantial drug quantities to the target when using these devices. Smart devices providing real-life objective information about a patient's adherence patterns and their inhaler technique are available.
Market Dynamics
The critical growth inducer for the pulmonary drug delivery devices market is the growing incidences of chronic respiratory disorders like tuberculosis, bronchitis, pneumonia, and asthma. Low efficacy of traditional treatment methods and better penetrability of drugs when using these devices will benefit market growth. Continued research and development to formulate new drugs and innovative delivery mechanisms to ensure minimal dosage will boost the market growth. The rising geriatric population and increased preference for minimally invasive treatment options will be a market booster. Rapid growth in the e-commerce sector will expand the growth of this market. Low drug absorption and enzymatic instability witnessed when using these devices will hinder the development of this market.
The report covers Porter's Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each segment in the global market of pulmonary drug delivery devices.
Market Segmentation
This section of the pulmonary drug delivery devices market report provides detailed data on the segments by analyzing them geographically, thereby assisting the strategist in identifying the target demographics for the respective product or service.
By Product
- Metered Dose Inhalers
- Dry Powder Inhalers
- Nebulizers
- Accessories
By Application
- Asthma
- Cystic Fibrosis
- COPD
- Allergic Rhinitis
- Others
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- E-Commerce
By End-Use
- Hospitals & Clinics
- Homecare
Regional Analysis
This section covers regional segmentation which accentuates on current and future demand for Pulmonary Drug Delivery Devices market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Pulmonary Drug Delivery Devices Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the pulmonary drug delivery devices market include GlaxoSmithKline plc,Philips Respironics,Boehringer Ingelheim GmbH,Novartis AG,3M Healthcare,GF Health Products, Inc.,Merck & Co., Inc.,AstraZeneca. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.